COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT03584802
Previous Study | Return to List | Next Study

Therapeutic Plasma Exchange, Rituximab and IV Ig for Severe Acute Exacerbation of IPF Admitted in ICU (EXCHANGE-IPF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03584802
Recruitment Status : Suspended (Owing to the Covid-19 epidemics, suspension of inclusions on Monday 16 march 2020 for an undetermined period of time)
First Posted : July 12, 2018
Last Update Posted : March 26, 2020
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : October 1, 2020
Estimated Study Completion Date : March 1, 2021